133454-47-4 | Iloperidone

Packsize	Purity	Availability	Price	Discounted Price
10mg	98%	in stock	$25.00	$18.00
25mg	98%	in stock	$44.00	$31.00
100mg	98%	in stock	$53.00	$37.00
250mg	98%	in stock	$73.00	$51.00
1g	98%	in stock	$122.00	$85.00
5g	98%	in stock	$390.00	$273.00
25g	98%	in stock	$1,590.00	$1,113.00

Description

• Catalog Number: AI30450
• Chemical Name: Iloperidone
• CAS Number: 133454-47-4
• Molecular Formula: C24H27FN2O4
• Molecular Weight: 426.4806
• MDL Number: MFCD00866688
• SMILES: COc1cc(ccc1OCCCN1CCC(CC1)c1noc2c1ccc(c2)F)C(=O)C

Computed Properties

• Complexity: 586
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 31
• Hydrogen Bond Acceptor Count: 7
• Rotatable Bond Count: 8
• XLogP3: 4.1

Literature

• A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.

  Toxicological sciences : an official journal of the Society of Toxicology 20131101

• Newer antipsychotics and upcoming molecules for schizophrenia.

  European journal of clinical pharmacology 20130801

• Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults.

  Expert review of clinical pharmacology 20130101

• New serotonin/dopamine antagonists for the treatment of schizophrenia: are we making real progress?

  Clinical schizophrenia & related psychoses 20121001

• Pharmacological and clinical profile of recently approved second-generation antipsychotics: implications for treatment of schizophrenia in older patients.

  Drugs & aging 20121001

• Iloperidone, asenapine and lurasidone: a primer on their current status.

  Expert opinion on pharmacotherapy 20120901

• Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.

  CNS drugs 20120901

• Clinically important differences in the pharmacokinetics of the ten newer 'atypical' antipsychotics: Part 2. Metabolism and elimination.

  Journal of psychiatric practice 20120901

• A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia.

  Expert opinion on pharmacotherapy 20120801

• Iloperidone (Fanapt®), a novel atypical antipsychotic, is a potent HERG blocker and delays cardiac ventricular repolarization at clinically relevant concentration.

  Pharmacological research 20120701

• Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians.

  Postgraduate medicine 20120701

• Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.

  Journal of managed care pharmacy : JMCP 20120601

• Clinically important differences in the pharmacokinetics of the ten newer 'atypical' antipsychotics: part 1.

  Journal of psychiatric practice 20120501

• Iloperidone for the treatment of schizophrenia: an updated clinical review.

  Clinical schizophrenia & related psychoses 20120401

• Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone.

  The Journal of clinical psychiatry 20120301

• Effects of quetiapine and sertindole on subchronic ketamine-induced deficits in attentional set-shifting in rats.

  Psychopharmacology 20120301

• Interactions between antiepileptics and second-generation antipsychotics.

  Expert opinion on drug metabolism & toxicology 20120301

• The pharmacogenetics of symptom response to antipsychotic drugs.

  Psychiatry investigation 20120301

• Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database.

  PLoS medicine 20120301

• The psychopharmacology of agitation: consensus statement of the american association for emergency psychiatry project Beta psychopharmacology workgroup.

  The western journal of emergency medicine 20120201

• Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.

  Human psychopharmacology 20120101

• The neuroprotective disease-modifying potential of psychotropics in Parkinson's disease.

  Parkinson's disease 20120101

• Trends in qualifying biomarkers in drug safety. Consensus of the 2011 meeting of the spanish society of clinical pharmacology.

  Frontiers in pharmacology 20120101

• Survey of methadone-drug interactions among patients of methadone maintenance treatment program in Taiwan.

  Substance abuse treatment, prevention, and policy 20120101

• Critical appraisal of lurasidone in the management of schizophrenia.

  Neuropsychiatric disease and treatment 20120101

• Atypical antipsychotic drugs, schizophrenia, and metabolic syndrome in non-Euro-American societies.

  Clinical neuropharmacology 20120101

• Angioedema occurring in patient prescribed iloperidone and haloperidol: a cross-sensitivity reaction to antipsychotics from different chemical classes.

  The Journal of neuropsychiatry and clinical neurosciences 20120101

• Biological perspectives: update on newer antipsychotic drugs: are they evidence based?

  Perspectives in psychiatric care 20111001

• Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis.

  JAMA 20110928

• Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis.

  Schizophrenia research 20110901

• Update on newer antipsychotic drugs.

  Journal of psychosocial nursing and mental health services 20110401

• Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics.

  Postgraduate medicine 20110301

• Iloperidone for the management of adults with schizophrenia.

  Clinical therapeutics 20110301

• Iloperidone: Does it have a meaningful place in therapy?

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110215

• Iloperidone: A new drug for the treatment of schizophrenia.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110215

• The role of serotonin receptors in the action of atypical antipsychotic drugs.

  Current opinion in pharmacology 20110201

• Atypical antipsychotics: the two new arrivals.

  Issues in mental health nursing 20110101

• Weight gain, obesity, and psychotropic prescribing.

  Journal of obesity 20110101

• The role of asenapine in the treatment of manic or mixed states associated with bipolar I disorder.

  Neuropsychiatric disease and treatment 20110101

• Role of sublingual asenapine in treatment of schizophrenia.

  Neuropsychiatric disease and treatment 20110101

• Genomewide association scan of suicidal thoughts and behaviour in major depression.

  PloS one 20110101

• Clinical potential of lurasidone in the management of schizophrenia.

  Therapeutics and clinical risk management 20110101

• Is the PANSS used correctly? a systematic review.

  BMC psychiatry 20110101

• Clinical utility of the risperidone formulations in the management of schizophrenia.

  Neuropsychiatric disease and treatment 20110101

• Iloperidone: a clinical overview.

  The Journal of clinical psychiatry 20110101

• Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion.

  Expert opinion on drug metabolism & toxicology 20101201

• A review of new atypical antipsychotic launches in the United States.

  Psychiatry (Edgmont (Pa. : Township)) 20101201

• The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis.

  The Journal of clinical psychiatry 20101001

• New antipsychotic drugs: how do their receptor-binding profiles compare?

  The Journal of clinical psychiatry 20100901

• Iloperidone for schizophrenia.

  Expert opinion on pharmacotherapy 20100801

• Iloperidone for the treatment of schizophrenia.

  Drugs of today (Barcelona, Spain : 1998) 20100801

• Atypical antipsychotic metabolism and excretion.

  Current drug metabolism 20100701

• Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic.

  International journal of clinical practice 20100501

• Iloperidone for the treatment of schizophrenia.

  The Annals of pharmacotherapy 20100501

• Absence of weight gain association with the HTR2C -759C/T polymorphism in patients with schizophrenia treated with iloperidone.

  Psychiatry research 20100227

• Iloperidone (Fanapt)--another second-generation antipsychotic.

  The Medical letter on drugs and therapeutics 20100222

• New drugs: asenapine, iloperidone, and bepotastine besilate.

  Journal of the American Pharmacists Association : JAPhA 20100101

• New atypical antipsychotics for schizophrenia: iloperidone.

  Drug design, development and therapy 20100101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20100101

• Iloperidone: a new option for the treatment of schizophrenia.

  Expert review of neurotherapeutics 20091201

• Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia.

  Molecular psychiatry 20091101

• Iloperidone: in schizophrenia.

  CNS drugs 20091001

• Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study.

  Molecular psychiatry 20090801

• Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic.

  International journal of clinical practice 20090801

• Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia.

  The Journal of clinical psychiatry 20090601

• Akathisia and second-generation antipsychotic drugs.

  Current opinion in psychiatry 20090501

• Further characterization of the discriminative stimulus properties of the atypical antipsychotic drug clozapine in C57BL/6 mice: role of 5-HT(2A) serotonergic and alpha (1) adrenergic antagonism.

  Psychopharmacology 20090401

• Pharmacogenomics: the promise of personalized medicine for CNS disorders.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20090101

• Genome-wide association studies in pharmacogenomics: untapped potential for translation.

  Genome medicine 20090101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20081001

• American psychiatric association.

  P & T : a peer-reviewed journal for formulary management 20080601

• New advances in the treatment of schizophrenia. Introduction.

  Journal of clinical psychopharmacology 20080401

• Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials.

  Journal of clinical psychopharmacology 20080401

• Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.

  Journal of clinical psychopharmacology 20080401

• Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.

  Journal of clinical psychopharmacology 20080401

• Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies.

  Journal of clinical psychopharmacology 20080401

• Effect of a ciliary neurotrophic factor polymorphism on schizophrenia symptom improvement in an iloperidone clinical trial.

  Pharmacogenomics 20080301

• Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market?

  Expert opinion on investigational drugs 20080101

• Gateways to clinical trials. July-August 2008.

  Methods and findings in experimental and clinical pharmacology 20080101

• Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability.

  Drugs 20080101

• Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats.

  Neuropharmacology 20060901

• Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interactions.

  Current medicinal chemistry 20040201

• Differential effects of iloperidone, clozapine, and haloperidol on working memory of rats in the delayed non-matching-to-position paradigm.

  Psychopharmacology 20030901

• Functional characterization of the novel antipsychotic iloperidone at human D2, D3, alpha 2C, 5-HT6, and 5-HT1A receptors.

  Life sciences 20030718

• alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs.

  European journal of pharmacology 20030221

• Effects of clozapine, haloperidol and iloperidone on neurotransmission and synaptic plasticity in prefrontal cortex and their accumulation in brain tissue: an in vitro study.

  Neuroscience 20030101

• Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism.

  Brain research 20021129

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20021101

• New antipsychotic agents for schizophrenia: pharmacokinetics and metabolism update.

  Current opinion in investigational drugs (London, England : 2000) 20020701

• Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone.

  Progress in neuro-psychopharmacology & biological psychiatry 20020401

• Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents.

  CNS drugs 20020101

• Iloperidone (Novartis).

  IDrugs : the investigational drugs journal 20020101

• Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20011201

• Treatments for chronic psychosis.

  Dialogues in clinical neuroscience 20011201

• Iloperidone (Hoechst Marion Roussel Inc).

  IDrugs : the investigational drugs journal 19990601

• Iloperidone binding to human and rat dopamine and 5-HT receptors.

  European journal of pharmacology 19961219

• The pharmacological profile of iloperidone, a novel atypical antipsychotic agent.

  The Journal of pharmacology and experimental therapeutics 19950901

• 3-[[(Aryloxy)alkyl]piperidinyl]-1,2-benzisoxazoles as D2/5-HT2 antagonists with potential atypical antipsychotic activity: antipsychotic profile of iloperidone (HP 873).

  Journal of medicinal chemistry 19950331

• The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs.

  Psychopharmacology bulletin 19890101